Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction:  Cerebral micro-embolic signals (MES) predict risk of stroke in carotid stenosis patients. However, MES-negative 'recently symptomatic patients' also have a higher stroke risk than 'asymptomatic patients'. Differences in platelet activation status may contribute to this disparity in risk.

Methods:  This prospective, observational study assessed platelet biomarkers and their relationship with MES in asymptomatic versus symptomatic moderate (≥50-69%) or severe (≥70-99%) carotid stenosis patients. Full blood count parameters were measured and whole-blood flow cytometry was used to quantify platelet surface CD62P and CD63 expression and leucocyte-platelet complex formation. Bilateral simultaneous transcranial Doppler ultrasound of the middle cerebral arteries classified patients as 'MES positive' or 'MES negative'.

Results:  Data from 34 asymptomatic patients were compared with those from 43 symptomatic patients in the 'early phase' (≤ 4 weeks) and 37 of these symptomatic patients in the 'late phase' (≥ 3 months) after transient ischaemic attack/ischaemic stroke. There were no differences in %CD62P or %CD63 expression between early or late symptomatic and asymptomatic patients overall ( > 0.05). The percentage of lymphocyte-platelet complexes was higher in early symptomatic than in asymptomatic patients (2.8 vs. 2.16%;  < 0.001). MES were more commonly observed in early symptomatic (31.4%;  = 0.027) but not in late symptomatic (6.7%;  = 0.996) versus asymptomatic patients (7.1%). The percentage of lymphocyte-platelet complexes was higher in early symptomatic than in asymptomatic MES-negative patients (2.7 vs. 2.17%;  = 0.02).

Conclusion: These data add to the evidence that leucocyte-platelet complex formation/platelet activation is increased in recently symptomatic versus asymptomatic patients, and may contribute to the pathogenesis of first and subsequent strokes in carotid stenosis patients, including those who are MES negative.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1678666DOI Listing

Publication Analysis

Top Keywords

carotid stenosis
12
stenosis patients
12
asymptomatic patients
12
patients
9
leucocyte-platelet complex
8
complex formation
8
symptomatic patients
8
symptomatic asymptomatic
8
symptomatic
7
asymptomatic
5

Similar Publications

Objective: The current selection of patients for carotid revascularisation is mainly based on neurological symptoms and the degree of carotid artery stenosis. Individualised MRI based PRediction scOre using plaque Vulnerability for symptomatic carotid artEry disease patients (IMPROVE) can identify high risk patients who may benefit from carotid revascularisation, based on intraplaque haemorrhage, stenosis severity, cerebral symptoms, sex, and age. For use in clinical trials and eventual practice, the decision rule must be acceptable to clinicians.

View Article and Find Full Text PDF

Purpose: Moyamoya disease (MMD) is a chronic cerebrovascular disorder characterized by progressive arterial stenosis and fragile collateral formation, elevating stroke risk. Revascularization is the standard treatment, yet up to 27% of patients experience ischemic events within a year due to bypass insufficiency. While digital subtraction angiography (DSA) remains the gold standard for assessing bypass function, it is invasive and time-consuming.

View Article and Find Full Text PDF

Background: Carotid artery stenosis is a major cause of stroke. Non-contrast MR angiography (MRA) using time-spatial labeling inversion pulse (Time-SLIP) may offer potential advantages over 3D time-of-flight (TOF)-MRA for simultaneous visualization of carotid, vertebral, and subclavian arteries, but remains uninvestigated.

Purpose: To determine optimal black blood inversion time (TI) for visualizing the carotid and subclavian arteries using three-dimensional (3D) fast field echo (FFE) Time-SLIP MRA, and to compare its image quality with 3D TOF-MRA.

View Article and Find Full Text PDF

Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by abnormal megakaryocyte proliferation and a markedly elevated platelet count, which predisposes patients to thrombotic or hemorrhagic events. Approximately 50%-60% of ET patients harbor a JAK2 V617F mutation. This mutation drives constitutive JAK kinase activation, promoting megakaryocyte proliferation and platelet production, while potentially activating inflammatory pathways and damaging vascular endothelium.

View Article and Find Full Text PDF

Efficacy and safety of protamine sulfate following carotid artery stenting.

Cardiovasc Revasc Med

September 2025

Division of Vascular Surgery, Cardiovascular Center, Tufts Medical Center, Boston, MA, USA; Tufts University School of Medicine, Boston, MA, USA. Electronic address:

Background: protamine sulfate is used to reduce bleeding risk after Carotid Artery Stenting (CAS), but its efficacy in personalized patient settings remains underexplored. This study aims to identify factors associated with greater benefits from protamine sulfate following CAS.

Methods: A retrospective review of Vascular Quality Initiative (VQI) data (2016-2022) identified patients undergoing CAS, divided into Transfemoral CAS (TF-CAS) and Transcarotid artery revascularization (TCAR) groups.

View Article and Find Full Text PDF